Studie - Diabetic Foot Infection (DFI) – Pipeline Review, H2 2012

Diabetic Foot Infection (DFI) — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'Diabetic Foot Infection (DFI) - Pipeline Review, H2 2012', provides an overview of the Diabetic Foot Infection (DFI) therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Foot Infection (DFI), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Foot Infection (DFI). 'Diabetic Foot Infection (DFI) - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope

- A snapshot of the global therapeutic scenario for Diabetic Foot Infection (DFI).
- A review of the Diabetic Foot Infection (DFI) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Diabetic Foot Infection (DFI) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Diabetic Foot Infection (DFI).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Diabetic Foot Infection (DFI) pipeline depth and focus of Diabetic Foot Infection (DFI) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Introduction 4

Global Markets Direct Report Coverage 4

Diabetic Foot Infection (DFI) Overview 5

Therapeutics Development 6

An Overview of Pipeline Products for Diabetic Foot Infection (DFI) 6

Diabetic Foot Infection (DFI) Therapeutics under Development by Companies 8

Late Stage Products 9

Comparative Analysis 9

Mid Clinical Stage Products 10

Comparative Analysis 10

Diabetic Foot Infection (DFI) Therapeutics — Products under Development by Companies 11

Companies Involved in Diabetic Foot Infection (DFI) Therapeutics Development 12

Basilea Pharmaceutica Ltd. 12

TaiGen Biotechnology Co., Ltd. 13

Innocoll, Inc. 14

Diabetic Foot Infection (DFI) — Therapeutics Assessment 15

Assessment by Monotherapy Products 15

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Drug Profiles 20

Nemonoxacin - Drug Profile 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

Cogenzia - Drug Profile 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Ceftobiprole Medocaril - Drug Profile 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Diabetic Foot Infection (DFI) Therapeutics — Drug Profile Updates 25

Diabetic Foot Infection (DFI) Therapeutics — Discontinued Products 26

Diabetic Foot Infection (DFI) — Product Development Milestones 27

Featured News & Press Releases 27

Mar 15, 2010: TaiGen's Nemonoxacin Once-A-Day Oral Dosing Meets Primary Endpoints In Diabetic Foot Infection Study 27

Appendix 28

Methodology 28

Coverage 28

Secondary Research 28

Primary Research 28

Expert Panel Validation 28

Contact Us 29

Disclaimer 29





List of Tables

Number of Products Under Development for Diabetic Foot Infection (DFI), H2 2012 6

Products under Development for Diabetic Foot Infection (DFI) — Comparative Analysis, H2 2012 7

Number of Products under Development by Companies, H2 2012 8

Comparative Analysis by Late Stage Development, H2 2012 9

Comparative Analysis by Mid Clinical Stage Development, H2 2012 10

Products under Development by Companies, H2 2012 11

Basilea Pharmaceutica Ltd., H2 2012 12

TaiGen Biotechnology Co., Ltd., H2 2012 13

Innocoll, Inc., H2 2012 14

Assessment by Monotherapy Products, H2 2012 15

Assessment by Stage and Route of Administration, H2 2012 17

Assessment by Stage and Molecule Type, H2 2012 19

Diabetic Foot Infection (DFI) Therapeutics — Drug Profile Updates 25

Diabetic Foot Infection (DFI) Therapeutics — Discontinued Products 26





List of Figures

Number of Products under Development for Diabetic Foot Infection (DFI), H2 2012 6

Products under Development for Diabetic Foot Infection (DFI) — Comparative Analysis, H2 2012 7

Products under Development by Companies, H2 2012 8

Late Stage Products, H2 2012 9

Mid Clinical Stage Products, H2 2012 10

Assessment by Monotherapy Products, H2 2012 15

Assessment by Route of Administration, H2 2012 16

Assessment by Stage and Route of Administration, H2 2012 17

Assessment by Molecule Type, H2 2012 18

Assessment by Stage and Molecule Type, H2 2012 19

• Diabetes – Pipeline Review, H1 2013
• Diabetic Foot Ulcers – Pipeline Review, H1 2013
• Diabetic Nephropathy – Pipeline Review, H1 2013
• Diabetic Neuropathy – Pipeline Review, H1 2013
• Type 2 Diabetes – Pipeline Review, H1 2013
• Global Insulin Antidiabetics Market 2012-2016
• Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth
• Adult Mouth Care in Romania
• Global Diabetes Drugs Market 2011-2015
• Argentina Diabetes Care Devices Market Outlook to 2018
• Asia-Pacific Diabetes Care Devices Market Outlook to 2018
• Australia Diabetes Care Devices Market Outlook to 2018
• Austria Diabetes Care Devices Market Outlook to 2018
• Belgium Diabetes Care Devices Market Outlook to 2018
• Brazil Diabetes Care Devices Market Outlook to 2018- Glucose Monitoring and Insulin Delivery
• Canada Diabetes Care Devices Market Outlook to 2018- Glucose Monitoring and Insulin Delivery
• Chile Diabetes Care Devices Investment Opportunities, Analysis and Forecasts to 2018
• China Diabetes Care Devices Market Outlook to 2018- Glucose Monitoring and Insulin Delivery
• Czech Republic Diabetes Care Devices Market Outlook to 2018
• Denmark Diabetes Care Devices Market Outlook to 2018